Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 1, Pages 322-337Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01360
Keywords
-
Categories
Funding
- Alexander von Humboldt Foundation, Germany
- Council of Scientific and Industrial Research, New Delhi
Ask authors/readers for more resources
The development of small molecule inhibitors targeting GPVI has promising therapeutic role, as they inhibit arterial thrombosis with limited risk of bleeding. Among the compounds showing in vivo antithrombotic activity, the most active compound 6b (ED50 = 28.36 mu mol/kg po in mice) showed improved inhibition for collagen (IC50 = 6.7 mu M), CRP-XL (IC50 = 53.5 mu M), and convuban (CVX) (IC50 = 5.7 /./M) mediated platelet aggregation as compared to losartan (LOS) (collagen, IC50 = 10.4 mu M; CRP-XL, IC50 = 158 /2M; CVX, IC50 = 11 1.4M) than any of its enantiomers S (6c) (collagen, IC50 = 25.3 mu M; CRP-XL, IC50 = 181.4 mu M; CVX, IC50 = 9 mu M) and R (6d) (collagen, IC50 = 126.3 mu M; CRP-XL, IC50 > 500 mu M, IC50 = 86.8 mu M). Compound 6b also inhibited platelet P-selectin expression and thus may diminish atherosclerosis. The molecular interactions of both enantiomers 6c and 6d at the GPVI receptor have been explained through docking studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available